Digene strengthens diagnostic patents:
This article was originally published in Clinica
US diagnostics company Digene has received a European patent for its Hybrid Capture technology. All of the company's tests are based on this technology, which uses signal amplification to detect as few as 100 molecules of DNA or RNA in a rapid format. The patent strengthens the company's protection for its human papillomavirus products and core technology, according to Beltsville, Maryland-based Digene.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.